Supriya Lifescience Share Price in Focus as it Updates on NDPS Act Proceedings Against General Manager Sreekant Sreedharan

Supriya Lifescience Limited has issued an update regarding judicial proceedings involving its General Manager, Sales & Marketing, Sreekant Sreedharan as per the exchange filings.  

The proceedings are under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985, for a procedural lapse. 

Details of the Judicial Proceedings 

On July 3, 2026, an investigation was initiated against Mr. Sreekant Sreedharan by the Special Investigation and Intelligence branch of the Customs Department.  

Following this, judicial custody was granted by the CMM court until July 17, 2026. The proceedings are related to a procedural lapse in a single export transaction. 

The company has stated that it remains committed to maintaining high standards of corporate governance and regulatory compliance. It is closely monitoring the developments in the case. 

Impact on Company Operations 

Supriya Lifescience has indicated that, based on the information currently available, the proceedings are not expected to have any material impact on its operations, financial position, or governance. The company is in the process of evaluating the implications of the proceedings and is obtaining appropriate legal advice. 

Read More: Sebi Reports Positive Response to Specialised Investment Funds with ₹13,500 Crore Asset Base! 

Company's Response and Legal Steps 

The company has communicated that it is evaluating the implications of the proceedings and is obtaining legal advice. It will disclose any further material developments to the stock exchanges as required by applicable laws and regulations. 

Conclusion 

Supriya Lifescience Limited has reported judicial proceedings against its General Manager, Sreekant Sreedharan, under the NDPS Act, 1985. The company does not expect these proceedings to have a material impact on its operations or financial position. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.